Daiqing Liao

Daiqing Liao, PhD

Associate Professor

Department: MD-ANATOMY
Business Phone: (352) 273-8188
Business Email: dliao@ufl.edu

About Daiqing Liao

Accomplishments

Term Professorship
2018-2021 · University of Florida
Exemplary Teacher
2015-2016 · University of Florida College of Medicine
American Lung Association of Florida Inc. Career Investigator Award
2003-2006 · ALAF
Canadian Foundation for Innovation Investigator Award
1998 · Canadian Foundation
Fonds de la Recherche en Santé du Québec Faculty Scholarship
1997-2000 · Santé du Québec
Medical Research Council of Canada Postdoctoral Fellowship
1995-1997 · Yale University

Teaching Profile

Courses Taught
2006-2023
GMS6647 Transcriptional and Translational Control of Cell Growth and Proliferation
2011-2012,2014-2021,2020-2023
DEN5121 Biochm Molec Cell Bio
2020-2024
GMS6691 Special Topics in Cell Biology and Anatomy
2014,2016-2020,2020-2024
GMS6421 Cell Biology
2016-2018,2020-2024
GMS6064 Tumor Biology
2016-2019
GMS6001 Fundamentals of Biomedical Sciences I
2018
GMS7979 Advanced Research
2018
GMS7980 Research for Doctoral Dissertation
2015-2016,2018-2023,2022-2024
GMS6009 Principles of Drug Action and Therapeutics
2014,2016-2018
GMS6062 Protein Trafficking
2008,2010-2016,2016
GMS6644 Apoptosis
2014
GMS6692 Research Conference in Anatomy and Cell Biology

Research Profile

Protein lysine acetyltransferases (KATs) catalyze the acetyl attachment to lysine side chains of protein substrates that include histones and many other cellular proteins. Deacetylases (HDACs) catalyze the reverse reaction to remove the attached acetyl group. Acetylation of protein substrates impacts their stability and functions in a variety of cellular pathways such as gene transcription, intracellular trafficking and metabolisms. Both KATs and HDACs are implicated in human diseases and represent rational therapeutic targets. The research in the Liao laboratory focuses on understanding cell-biological functions of these enzymes in virology, epigenetics and cancer biology, as well as on discovery, characterization, and optimization of novel small-molecule inhibitors of these enzymes for cancer therapy. In collaboration with the high-throughput screen facilities at Scripps Florida at Jupiter and the Sanford Burnham Medical Research Institute at Lake Nona, we aim at identifying novel lead KAT and HDAC inhibitors. We use in vitro biochemical as well as cell-based assays to validate their activities. We also collaborate with medicinal chemists to optimize the lead compounds to improve the target potency and specificity as well as drug-like properties of the lead compounds. We use mouse tumor models to determine in vivo anticancer efficacy of the small-molecule inhibitors. Ultimately, our optimized KAT and HDAC inhibitors may lead to novel therapy for treating cancer patients and other human diseases.

Open Researcher and Contributor ID (ORCID)

0000-0002-2948-2694

Publications

2023
Abstract 5347: Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs
Cancer Research. 83(7_Supplement):5347-5347 [DOI] 10.1158/1538-7445.am2023-5347.
2023
Abstract LB002: Extracellular vesicle loading of proteolysis targeting chimeras for targeted therapeutic delivery
Cancer Research. 83(8_Supplement):LB002-LB002 [DOI] 10.1158/1538-7445.am2023-lb002.
2023
DAXX drives de novo lipogenesis and contributes to tumorigenesis
Nature Communications. 14(1) [DOI] 10.1038/s41467-023-37501-0. [PMID] 37045819.
2023
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation.
Cell chemical biology. 30(11):1421-1435.e12 [DOI] 10.1016/j.chembiol.2023.07.010. [PMID] 37572669.
2023
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy
Life Medicine. 2(3) [DOI] 10.1093/lifemedi/lnad019.
2022
Abstract LB138: DAXX interacts with sterol regulatory element-binding proteins (SREBPs) to promote oncogenic lipogenesis and tumorigenesis in triple-negative breast cancer
Cancer Research. 82(12_Supplement):LB138-LB138 [DOI] 10.1158/1538-7445.am2022-lb138.
2022
Apoptosis, necroptosis, and pyroptosis in health and disease
Mechanisms of Cell Death and Opportunities for Therapeutic Development. 1-46 [DOI] 10.1016/b978-0-12-814208-0.00008-7.
2022
Ferroptosis
Mechanisms of Cell Death and Opportunities for Therapeutic Development. 261-277 [DOI] 10.1016/b978-0-12-814208-0.00005-1.
2022
Protein phase separation in cell death and survival
Mechanisms of Cell Death and Opportunities for Therapeutic Development. 175-195 [DOI] 10.1016/b978-0-12-814208-0.00004-x.
2021
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Cancers. 13(12) [DOI] 10.3390/cancers13122872. [PMID] 34201346.
2021
Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer
Cancers. 13(11) [DOI] 10.3390/cancers13112799. [PMID] 34199844.
2020
Assays for Validating Histone Acetyltransferase Inhibitors.
Journal of visualized experiments : JoVE. (162) [DOI] 10.3791/61289. [PMID] 32831305.
2020
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Chemical Communications. 56(68):9866-9869 [DOI] 10.1039/d0cc03243c. [PMID] 32840532.
2020
Two-Way Horizontal and Vertical Omics Integration for Disease Subtype Discovery
Statistics in Biosciences. 12(1):1-22 [DOI] 10.1007/s12561-019-09242-6.
2019
Abstract 4718: SR-4370, a potent and selective inhibitor of class I HDACs, suppresses AR signaling and in vivo prostate tumor growth
Cancer Research. 79(13_Supplement):4718-4718 [DOI] 10.1158/1538-7445.am2019-4718.
2019
Abstract 5214: Targeting the estrogen receptor pathway in luminal breast cancer through inhibition of p300/CBP
Cancer Research. 79(13_Supplement):5214-5214 [DOI] 10.1158/1538-7445.am2019-5214.
2019
DAXX in cancer: phenomena, processes, mechanisms and regulation.
Nucleic acids research. 47(15):7734-7752 [DOI] 10.1093/nar/gkz634. [PMID] 31350900.
2018
Abstract 1473: Role of acetyltransferases CBP and p300 in de novo fatty acid synthesis in colorectal cancer
Cancer Research. 78(13_Supplement):1473-1473 [DOI] 10.1158/1538-7445.am2018-1473.
2018
Abstract 3953: The role of USF1 in the regulation of lipogenesis and breast cancer tumor progression
Cancer Research. 78(13_Supplement):3953-3953 [DOI] 10.1158/1538-7445.am2018-3953.
2018
Abstract B004: A combination of two chemically distinct inhibitors of class I HDACs is highly effective to suppress AR signaling and in vivo growth of prostate cancer xenograft
Cancer Research. 78(16_Supplement):B004-B004 [DOI] 10.1158/1538-7445.prca2017-b004.
2018
Abstract LB-248: Chemically distinct class I HDAC inhibitors synergize to inhibit global lipid metabolism in cancer
Cancer Research. 78(13_Supplement):LB-248 [DOI] 10.1158/1538-7445.am2018-lb-248.
2018
Degradation of DAXX by adenovirus type 12 E1B-55K circumvents chemoresistance of ovarian cancer to cisplatin.
Virology. 521:118-128 [DOI] 10.1016/j.virol.2018.05.026. [PMID] 29906705.
2018
Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival
The Prostate. 78(15):1140-1156 [DOI] 10.1002/pros.23689. [PMID] 30009471.
2018
βArrestin2 Mediates Renal Cell Carcinoma Tumor Growth
Scientific Reports. 8(1) [DOI] 10.1038/s41598-018-23212-w. [PMID] 29559707.
2017
Abstract 4132: Roles of the acetyltransferases CBP/p300 in breast cancer
Cancer Research. 77(13_Supplement):4132-4132 [DOI] 10.1158/1538-7445.am2017-4132.
2017
Abstract LB-266: DAXX promotes de novo lipogenesis in triple-negative breast cancer
Cancer Research. 77(13_Supplement):LB-266 [DOI] 10.1158/1538-7445.am2017-lb-266.
2016
Intrinsic cellular signaling mechanisms determine the sensitivity of cancer cells to virus-induced apoptosis.
Scientific reports. 6 [DOI] 10.1038/srep37213. [PMID] 27849011.
2015
Acetylation of HDAC1 and degradation of SIRT1 form a positive feedback loop to regulate p53 acetylation during heat-shock stress.
Cell death & disease. 6(5) [DOI] 10.1038/cddis.2015.106. [PMID] 25950477.
2015
Identification and characterization of small-molecule inhibitors of lysine acetyltransferases.
Methods in molecular biology (Clifton, N.J.). 1238:539-48 [DOI] 10.1007/978-1-4939-1804-1_28. [PMID] 25421679.
2015
Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
Chemistry & biology. 22(2):273-84 [DOI] 10.1016/j.chembiol.2014.12.015. [PMID] 25699604.
2015
Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors
Genomics Data. 5:257-259 [DOI] 10.1016/j.gdata.2015.06.019. [PMID] 26217556.
2015
Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors
Drug Discovery Today: Technologies. 18:24-28 [DOI] 10.1016/j.ddtec.2015.10.006. [PMID] 26723889.
2014
Identification and Characterization of Class I Hdac-Specific Small-Molecule Inhibitors With a Novel Pharmacophore
Cancer Research. 74(19, S):2525-2525 [DOI] 10.1158/1538-7445.AM2014-2525.
2014
Overexpression of Histone Deacetylases in Cancer Cells Is Controlled By Interplay of Transcription Factors and Epigenetic Modulators
The FASEB's Journal. 28(10):4265-4279 [DOI] 10.1096/fj.14-250654. [PMID] 24948597.
2013
Abstract 742: Up-regulation of histone deacetylases in colon cancer.
Cancer Research. 73(8_Supplement):742-742 [DOI] 10.1158/1538-7445.am2013-742.
2013
Abstract PR16: A new class of small molecule acetyltransferase inhibitors discovered through high-throughput screening are potent anticancer agents with cancer-type specific activity
Cancer Research. 73(13_Supplement):PR16-PR16 [DOI] 10.1158/1538-7445.cec13-pr16.
2013
p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1.
Molecular biology of the cell. 24(17):2739-52 [DOI] 10.1091/mbc.E12-10-0771. [PMID] 23825024.
2013
Small-Molecule Inhibitors of Acetyltransferase P300 Identified By High-Throughput Screening Are Potent Anticancer Agents (Vol 12, Pg 610, 2013)
Molecular Cancer Therapeutics. 12(8):1688-1688 [DOI] 10.1158/1535-7163.MCT-13-0441.
2012
Abstract 4763: Targeting p300 for inhibiting triple negative breast cancer
Cancer Research. 72(8_Supplement):4763-4763 [DOI] 10.1158/1538-7445.am2012-4763.
2012
Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
Cell cycle (Georgetown, Tex.). 11(3):582-93 [DOI] 10.4161/cc.11.3.19052. [PMID] 22262167.
2011
Abstract 613: Depletion of Mdm2 and Mdm4 by adenovirus: Molecular mechanism and anticancer therapeutic implication
Cancer Research. 71(8_Supplement):613-613 [DOI] 10.1158/1538-7445.am2011-613.
2011
In pursuit of new anti-angiogenic therapies for cancer treatment.
Frontiers in bioscience (Landmark edition). 16(3):803-14 [PMID] 21196204.
2011
Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents.
Journal of virology. 85(16):7976-88 [DOI] 10.1128/JVI.00492-11. [PMID] 21680522.
2010
Abstract 4517: HDAC inhibitors suppress p53 expression through transcriptional repression: Implication for therapy against metastatic breast cancer
Cancer Research. 70(8_Supplement):4517-4517 [DOI] 10.1158/1538-7445.am10-4517.
2009
Emerging roles of the EBF family of transcription factors in tumor suppression.
Molecular cancer research : MCR. 7(12):1893-901 [DOI] 10.1158/1541-7786.MCR-09-0229. [PMID] 19996307.
2009
Identification of two independent SUMO-interacting motifs in Daxx: evolutionary conservation from Drosophila to humans and their biochemical functions.
Cell cycle (Georgetown, Tex.). 8(1):76-87 [PMID] 19106612.
2007
Repression of p53-mediated transcription by adenovirus E1B 55-kDa does not require corepressor mSin3A and histone deacetylases.
The Journal of biological chemistry. 282(10):7001-10 [PMID] 17209038.
2006
An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis.
Cancer research. 66(19):9445-52 [PMID] 17018599.
2006
Synthesis, crystal structure, and characterization of new tetranuclear Ag(I) complexes with triazole bridges.
Inorganic chemistry. 45(15):5822-9 [PMID] 16841987.
2005
Synthesis, crystal structures, and properties of oxovanadium(IV)-lanthanide(III) heteronuclear complexes.
Chemistry (Weinheim an der Bergstrasse, Germany). 11(17):5031-9 [PMID] 15973746.
2004
Negative regulation of p53 functions by Daxx and the involvement of MDM2.
The Journal of biological chemistry. 279(48):50566-79 [PMID] 15364927.
2003
Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates enhancement of p53-dependent transcription by Daxx.
Journal of virology. 77(21):11809-21 [PMID] 14557665.
2003
PCAF is a coactivator for p73-mediated transactivation.
Oncogene. 22(51):8316-29 [PMID] 14614455.
2003
Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis.
Journal of virology. 77(24):13171-81 [PMID] 14645574.
2000
Activation of p53 or loss of the Cockayne syndrome group B repair protein causes metaphase fragility of human U1, U2, and 5S genes.
Molecular cell. 5(5):801-10 [PMID] 10882116.
2000
Adenovirus E1B 55-Kilodalton Oncoprotein Inhibits p53 Acetylation by PCAF
Molecular and Cellular Biology. 20(15):5540-5553 [DOI] 10.1128/mcb.20.15.5540-5553.2000. [PMID] 10891493.
2000
Gene conversion drives within genic sequences: concerted evolution of ribosomal RNA genes in bacteria and archaea.
Journal of molecular evolution. 51(4):305-17 [PMID] 11040282.
1999
Concerted evolution of the tandem array encoding primate U2 snRNA (the RNU2 locus) is accompanied by dramatic remodeling of the junctions with flanking chromosomal sequences.
The EMBO journal. 18(13):3783-92 [PMID] 10393193.
1999
Concerted evolution: molecular mechanism and biological implications.
American journal of human genetics. 64(1):24-30 [PMID] 9915939.
1998
Characterization of a novel class of interspersed LTR elements in primate genomes: structure, genomic distribution, and evolution.
Journal of molecular evolution. 46(6):649-60 [PMID] 9608047.
1997
Concerted evolution of the tandemly repeated genes encoding human U2 snRNA (the RNU2 locus) involves rapid intrachromosomal homogenization and rare interchromosomal gene conversion.
The EMBO journal. 16(3):588-98 [PMID] 9034341.
1996
A NusG-like protein from Thermotoga maritima binds to DNA and RNA.
Journal of bacteriology. 178(14):4089-98 [PMID] 8763936.
1995
Concerted evolution of the tandemly repeated genes encoding primate U2 small nuclear RNA (the RNU2 locus) does not prevent rapid diversification of the (CT)n.(GA)n microsatellite embedded within the U2 repeat unit.
Genomics. 30(3):583-93 [PMID] 8825646.
1994
Molecular phylogenies based on ribosomal protein L11, L1, L10, and L12 sequences
Journal of Molecular Evolution. 38(4):405-419 [DOI] 10.1007/bf00163157.
1993
The Evolution of Ribosomal Protein and Ribosomal RNA Operons: Coding Sequences, Regulatory Mechanisms and Processing Pathways
The Translational Apparatus. 679-688 [DOI] 10.1007/978-1-4615-2407-6_64.
1992
The organization and expression of essential transcription translation component genes in the extremely thermophilic eubacterium Thermotoga maritima.
The Journal of biological chemistry. 267(32):22787-97 [PMID] 1429627.
1987
THE APPLICATION OF STRUCTURAL DATA TO THE RESEARCH ON CHEMICAL REACTION PATHWAYS,<br>I. DYNAMIC STEREOCHEMISTRY OF FIVECOORDINATE MOLYBDENUM COMPOUNDS Mo(L)<SUB>5</SUB>
Acta Physico-Chimica Sinica. 3(05):449-452 [DOI] 10.3866/pku.whxb19870501.
1986
X-Ray crystal structure of the unusual clathrate compound, [Mo36O110(NO)4(H2O)14]·52H2O
J. Chem. Soc., Chem. Commun.. (11):835-836 [DOI] 10.1039/c39860000835.

Grants

Apr 2023 ACTIVE
Oncogenic signaling that promotes lipid synthesis and resistance to ferroptosis
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Apr 2022 ACTIVE
Development of first-in-class HDAC3-selective degraders for breast cancer therapy
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
May 2021 – Apr 2024
Novel Mechanism of Action and Translational Potential of the HDAC Inhibitor SR-4370 for Treating Breast Cancer
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jul 2020 – Dec 2022
OR-DRPD-ROF2020: Exploration of the SIM2 class as potential novel peptide anticancer therapeutics
Role: Principal Investigator
Funding: UF RESEARCH
Jun 2020 – Nov 2023
Molecular mechanisms and pharmacologic targeting of lipogenesis in breast cancer
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Feb 2018 – Jan 2019
Novel isoform-selective HDAC inhibitor for enhancing cancer immunotherapy against breast cancer
Role: Principal Investigator
Funding: FL BREAST CANCER FOU
Mar 2016 – Aug 2019
PHARMACOLOGIC INHIBITION OF ACETYLTRANSFERASE CBP/P300 AS ANEW THERAPEUTIC APPROACH FOR BREAST CANCER
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Mar 2016 – Feb 2017
TARGET HDAC2 FOR TREATING ER-POSITIVE AND DRUG-RESISTANTBREAST CANCER
Role: Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Feb 2015 – Oct 2023
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2015 ACTIVE
UF Health Cancer Center Bridge Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2007 – Oct 2018
Consolidated UF Shands Cancer Center Research
Role: Project Manager
Funding: UF FOUNDATION

Education

Postdoctoral Training
1994-1997 · Yale University School of Medicine
PhD
1993 · University of British Columbia, Canada
MS
1986 · Peking University, China
BS
1983 · Hunan University, China

Contact Details

Phones:
Business:
(352) 273-8188
Emails:
Business:
dliao@ufl.edu
Addresses:
Business Mailing:
PO Box 103633
GAINESVILLE FL 32610
Business Street:
CGRC 456
2033 MOWRY RD
GAINESVILLE FL 32610